Allos Therapeutics 2Q loss widens on costs
News | 29 July 2010
Biotechnology company Allos Therapeutics Inc. said Wednesday its second-quarter loss widened on higher costs associated with sales of the cancer drug ...
Click on the link to read the full article at BusinessWeek
(This link will open in a new window)
- GlaxoSmithKline’s Avandia still available in UK, despite MHRA call for its suspension
- Israel relaxes restrictions on medical marijuana; scientists develop new HIV/AIDS treatment
- Tough road ahead for some generics after USA’s Federal Circuit Patent Use Code decisions
- Bausch & Lomb moves to acquire Miochol-E from Novartis as required by US competition authority
- German drug price curbs will hamper orphan drug development, says BIO Deutschland
